Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Braz. j. med. biol. res ; 51(8): e7440, 2018. graf
Article in English | LILACS | ID: biblio-951737

ABSTRACT

Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple pharmacological treatments have been proposed to alter the articular structure with potential benefit in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects in decreasing the risk of fractures and possible effect in reducing the progression of OA. The objective of this review was to demonstrate the current panorama of knowledge on the use of SrRan in clinical and experimental models, clarifying its mechanisms of action and describing possible anti-nociceptive and anti-inflammatory effects. The systematic review was based on the PRISMA statement and included articles that are indexed in scientific databases. Fifteen studies were included: seven pre-clinical and eight clinical studies. Despite the limited number of studies, the results suggest a positive effect of SrRan in patients with OA, through changes in functional capacity and reduction of progression of morphological parameters and joint degradation, with moderate quality of evidence for those clinical outcomes. Novel studies are necessary to elucidate the molecular targets of SrRan, focusing on anti-inflammatory effects and histological changes promoted by SrRan, which seemed to reduce the progression of OA in the experimental and clinical studies.


Subject(s)
Humans , Animals , Osteoarthritis/drug therapy , Thiophenes/therapeutic use , Bone Density Conservation Agents/therapeutic use , Thiophenes/pharmacology , Bone Resorption/drug therapy , Cartilage, Articular/drug effects , Bone Remodeling/drug effects , Disease Progression , Arthralgia/drug therapy , Bone Density Conservation Agents/pharmacology
2.
Vector Borne Zoonotic Dis ; 15(11): 694-700, 2015.
Article in English | LILACS, SES-SP, SESSP-IALPROD, SES-SP, SESSP-IALACERVO | ID: biblio-1022067

ABSTRACT

Arenavirus Sabiá was originally isolated from a fatal human infection in Brazil, and after the occurrence of the second fatal human case in São Paulo state, epidemiologic and virologic studies were performed in the area where the patient lived, aiming at the identification of the Sabiá natural rodent reservoir. A broadly cross-reactive enzyme-linked immunosorbent assay (ELISA) was used to screen for antibody-positive samples. Antibodies to arenavirus were detected in two of the 55 samples of Calomys tener, and from these results, samples of rodents were analyzed by a broad RT-PCR assay. RT-PCR amplification detected arenavirus sequences in five of the 55 C. tener samples, and sequencing showed that this virus is a distinct form of Sabiá virus. Thus, we describe here the evidence for the circulation of a new arenavirus in Brazil (proposed name Pinhal virus) and its genetic characterization compared to other arenaviruses. This study also suggests C. tener as a probable rodent reservoir for this virus and associates this new virus with the lineage C of New World arenaviruses. Although we have defined some characteristics of this virus, so far, there is no evidence of its involvement in human disease.


Subject(s)
Phylogeny , Brazil/epidemiology , Disease Reservoirs/veterinary , Enzyme-Linked Immunosorbent Assay , Sigmodontinae/virology , Arenaviruses, New World/isolation & purification , Arenaviruses, New World/classification , Arenaviruses, New World/genetics , Arenaviridae Infections/veterinary , Arenaviridae Infections/virology , Animals , Antibodies, Viral/blood
SELECTION OF CITATIONS
SEARCH DETAIL